We would love to hear your thoughts about our site and services, please take our survey here.
MCCI contract win
Offering power buffering in Adafruit Feather form factor designed for open-source maker community, MCCI's Model 4906 Supercap FeatherWing LoRa Module features a 1F CAP-XX supercap to store energy and deliver burst power for wireless transmissions in IoT devices
Oracle Power PLC (AIM:ORCP), the international natural resources project developer, is pleased to share a short Information Memorandum in relation to the Company's proposed green hydrogen project in ****stan.
The Information Memorandum provides an overview of the project, including proposed capacity, specifications of the facility, targeted market, expected costs, pricing goals and a development update. Energy from green hydrogen production is internationally regarded as a key potential fuel for a carbon neutral future and hydrogen production projects are increasingly being adopted internationally. Oracle is well positioned and plans to be the first to set up a hydrogen production facility in ****stan, a targeting a globally competitive cost of approximately US$2 per kg of Hydrogen.
Oracle is confident that the planned facility would produce green hydrogen at a relatively low price given the decreasing cost of renewable power and the comparative advantage of low cost production in ****stan. The project aims to bring the cost of green hydrogen below US$2 per kg once operational at full capacity.
We note the apparent similarities between the Graff discovery and the prospectivity in our own licence, which is highly encouraging especially when combined with the strong economics of our prospects
https://twitter.com/afzalvalli/status/1490662617802752005?s=21
Completion of Tender Offer
and
Exercise of Options/RSUs
Further to the announcements of 14 January 2022 and 3 February 2022, Minds + Machines Group Limited (AIM: MMX) is pleased to announce the completion of its Tender Offer.
The Company confirms the Tender Offer was fully subscribed and 182,692,308 Ordinary Shares have been purchased at a price of 10.4 pence per Ordinary Share, for aggregate consideration of £19 million. Tenders for up to and including the Tender Offer Entitlement of 1 Ordinary Share for every 1.485 Ordinary Shares were met in full, representing approximately 93.35% of the Ordinary Shares being purchased by the Company. In addition, 16.59832% of shares tendered in excess of a shareholders Basic Entitlement will be purchased, accounting for the remaining 6.65% of the Ordinary Shares being bought back under the Tender Offer, The Ordinary Shares to be purchased under the Tender Offer represent approximately 67.3% of the current Ordinary Shares in issue.
All of the 182,692,308 Ordinary Shares bought back have been cancelled by the Company.
Northern Drillholes at Clarke Intercept Additional Gold Mineralisation
Additional Rare Earth Interceptions Directly Above Gold Zones
Cobra, a gold exploration company focused on the Wudinna Gold Project in South Australia, announces additional results from the Company's recent 14-hole phase of Reverse Circulation ("RC") drilling on the Clarke prospect. The Company is pleased to report:
· Further gold mineralisation has been intercepted within the northern drill transect confirming the potential for a significant gold mineral system at Clarke
· Additional Rare Earth Elements ("REE") have been intercepted above and proximal to gold interceptions. The Board considers the discovery of critical REEs overlaying gold mineralisation to be significant, with grades and intercept widths (summarised further below) comparable to other rare earth projects of considerable market value. This discovery now exposes Cobra to multiple high value commodities
Fire assay results for gold have now been received for all holes in the recent phase of drilling on the Clarke prospect, multi-element and rare earth results are outstanding for a single hole
Highlights:
· Lead engineering consultant Practara (Pty) Limited has developed a number of recommendations to be adopted aimed at including near-surface mineralisation into the Resource Model
· Project design engineers Nurizon will review plant layout specifically to offer multiple options for presentation to the Namibian authorities for consideration
· Further guidance will be provided by specialist Namibian environmental consultants, Namisun Environmental Projects and Development, managing a consortium of local experts given the responsibility for environmental impact assessment documentation
· Plant design consultants will embark on high-level design based on feedback from the Company and consultants referencing project throughput, ore types, scheduling and life of mine
· Current 2,000 metre drill programme objectives to be realigned with the Mining Licence application process with a short-term emphasis on:
o twinning historic drill holes to provide invaluable geological data
o completion of initial geotechnical logging for engineering purposes including the siting of infrastructure and underground development
o collection of drill core for detailed metallurgical test work
o drilling to intersect near-surface copper (gold) oxide potential and to refine the geological model
LUPUZOR™ UPDATE
PK study commencement approved by MHRA - patient dosing to commence imminently
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide an update on the Lupuzor™ pharmacokinetic ("PK") study, as part of the new optimised international Phase 3 trial of Lupuzor™ in Lupus patients.
Key highlights
· Medical and Health Products Regulatory Agency ("MHRA") approves commencement of the PK study
· Volunteers have been selected and approved for inclusion in the PK study
· Volunteer dosing to commence on 15 February 2022
· Study on track to deliver results around the end Q1 2022
Following the approval from the US Food & Drug Administration ("FDA") of the protocol for the pharmacokinetic ("PK") study and local Ethics committee approval, ImmuPharma has been working with Avion Pharmaceuticals ("Avion"), our exclusive US partner, and our Contract Research Organisation ("CRO"), Simbec-Orion, together with additional specialist service providers, to prepare the commencement of the study.
As part of the regulatory process, the Investigational Medicinal Product Dossier ("IMPD") required significant revision, due to the inclusion of a new proprietary synthesis of P140, which consequently affords greater IP protection and lower cost of goods. The new IMPD was submitted to the MHRA and, following a full review, the MHRA has approved the commencement of the PK study.
The PK study is a Phase I study to assess the presence of Lupuzor™ in the body after administration of a single dose. The study will be carried out in a total of up to 24 healthy male volunteers.
Volunteers have been selected and approved with dosing to commence on 15 February 2022. As previously advised, we expect study results to be available around the end of Q1 2022.
Salta operations update
Well DP-2001
The first of the wells drilled in the current programme at the Dos Puntitas field, Puesto Guardian Concession is now in production and flowing the first commercial oil from a new well in the Concession for the first time in the last 12 years.
It is early days and the Company is in the process of testing to assess optimum steady state levels and performance. The positive news is that the well is successfully cleaning up and producing 90% oil with little water. Further announcements will be made after the well has been stabilised.
Well DP-2003
The second well in the programme is being tested with results expected to be able to be announced by the end of this week.
Highlights
· First pass Reverse Circulation ("RC") programme with 62 holes, to a depth of 120m, for a total of 7,440m has commenced.
· Maiden drill testing of a previously unrecognised greenstone belt with the objective to confirm its presence.
· Drilling to focus on five priority areas identified from a comprehensive geochemical programme conducted in 2021 (see announcement of 31 August 2021 for further details).
· The drill programme is expected to take between 4 to 5 weeks with results expected approximately six to eight weeks from completion, subject to laboratory availability.